Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 451-462

  Chilton, C H ^a   Crowther, G S ^a   Freeman, J ^b   Todhunter, S L ^a   Nicholson, S ^a   Longshaw, C M ^c   Wilcox, M H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Antimicrobial persistence; Recurrence; Spores

Indexed keywords

CLINDAMYCIN; FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CHEMOSTAT; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SIMULATION; DRUG EFFICACY; DRUG INSTILLATION; DRUG TREATMENT FAILURE; FECES; IN VITRO STUDY; INTESTINE; INTESTINE FLORA; LIMIT OF DETECTION; NONHUMAN; RECURRENT INFECTION;

ANTIMICROBIAL PERSISTENCE; RECURRENCE; SPORES;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL TRACT; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; TREATMENT FAILURE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84892459948     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt347     Document Type: Article

References (29)

1. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-49.
2. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
3. Ghantoji SS, Sail K, Lairson DR et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74:309-18.
4. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 Suppl 2: S93-103.
5. MacFarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
6. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
7. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
8. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-72.
9. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
10. Chilton CH, FreemanJ, Crowther GS et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012; 67:2434-7.
11. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
12. Baines SD, O'Connor R, Saxton K et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
13. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
14. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-10.
15. Cornely OA, Miller MA, Louie TJ et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 Suppl 2: S154-61.
16. Wilcox MH. Progress with a difficult infection. Lancet Infect Dis 2012; 12:256-7.
17. Chan WC, Leyland M, Clark J et al. Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. FEBS Lett 1996; 390: 129-32.
18. Rayman MK, Aris B, Hurst A. Nisin: a possible alternative or adjunct to nitrite in the preservation of meats. Appl Environ Microbiol 1981; 41:375-80.
19. Chilton CH, Freeman J, Baines SD et al. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. J Antimicrob Chemother 2013; 68: 2078-82.
20. Allen CA, Babakhani F, Sears P et al. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother 2013; 57: 664-7.
21. Heeg D, Kuehne SA, Dempster AW et al. Analysis of spore formation, germination and outgrowth of six clinically-relevant Clostridium difficile polymerase chain reaction (PCR)-ribotypes challenged with fidaxomicin. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 2013. Abstract P1140, p.110. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
22. Chilton CH, Crowther GS, Todhunter SL et al. Fidaxomicin persistence in an in vitro human gut model, and adherence to Clostridium difficile spores. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 2013. Abstract P1129, p. 109. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
23. Wilcox MH, Fawley WN, Settle CD et al. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998;38: 93-100.
24. Louie TJ, Miller MA, MullaneKM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
25. Babakhani F, Gomez A, Robert N et al. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 2011; 55: 4427-9.
26. European Medicines Agency. DIFICLIR Public Assessment Report. 22 September 2011. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/human/002087/WC500119707. pdf (13 March 2013. date last accessed).
27. Figueroa I, Johnson S, Sambol SP et al. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012; 55 Suppl 2: S104-9.
28. Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 Suppl 2: S132-42.
29. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156: 3354-9.